Considering its favorable clinical efficacy and safety, and the inhibitory activity against the ALK-resistant mutants including L1196M, C1156Y, and ALK-G1202R (16, 18), iruplinalkib is a cost-effective option for patients with ALK-positive crizotinib-resistant Advanced NSCLC in China. This evidence concerns the gene ALK and non-small cell lung carcinoma.